

Karolinska Development AGM 2021: Information on candidates nominated for election to the board (re election)

Tse Ping

Born 1952. Honorary Doctorate, Fil Dr hc.

Vice Chairman and Board member since 2015.

Other appointments, Founder and CEO of Sino Biopharmaceutical Limited, Chairman and executive director of Hong Kong listed Lamtex Holdings Ltd, Vice Chairman of Charoen Pokphand Group, where he has extensive experience of major mergers and acquisition activity including Ping AN Insurance, CITIC Group, China Mobile, ITOCHU Corporation and Marko Group.

Previous appointments include Member of the Ninth, Tenth, and Eleventh National Committee of the Chinese People's Political Consultative Conference.

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 75,727,285 shares (by related legal person).

Theresa Tse

Born 1992. Bachelor's degree of Science in Economics from the Wharton School of University of Pennsylvania.

Board Member since 2017.

Other appointments, Executive Director, the Chairlady of the Board and the Chairlady of the Executive Board Committee and the Nomination Committee, respectively, of Sino Biopharmaceutical Ltd (listed in Hong Kong).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 75,727,285 shares (by related legal person).

Björn Cochlovius

Born 1968. Ph.D., Assoc.Prof.

Board Member since 2020 and Chairman since 2020.

Other appointments Chairman of Isogenia Ltd, founder and General Manager in BC BioMed Consulting GmbH, Partner in Jürg Kurmann Merger and Acquisitions AG, Associate Professor Immunology at Ruprecht-Karls Universität Heidelberg.

Previous assignments include Senior Director Development Asia-Pacific in Abbvie Inc., member and Head Oncology in Otsuka, co-founder, Interim-CEO and Chairman in Ciliatech AG, Director Business Development Oncology in Roche AG, internal strategy consultant with Alpharma AS (nowadays Axellia), acting CEO of OnTarget Neurology AS, Head R&D at Affitech AS.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

Anna Lefevre Skjöldebrand

Born 1969. Masters of Law.

Board Member since 2021.

Other appointments CEO, Swedish Medtech Service AB. Current board assignments include Sweden Medtech4Health AB (chairperson), Dedicare AB, Swecare, COCIR, member of the advisory board Life Science office of Sweden.

Previous assignments include Head of Legal Swedish Medtech Service AB, Lawyer Delphi & Co, Lawyer GLS Legal, Lawyer Ernst & Young Law, Legal Counsel Front Capital Systems AB. Previous board assignments include The e-Health agency, SIS AB and Medtech Europe. She has also been a member of the board in the Board for Public Procurement.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

Ben Toogood

Born 1976, BPharm. MSc. MBA

Board Member since 2021.

Other appointments, Head Global Business Development, Sino Biopharmaceuticals Limited.

Previous assignments, Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories), Regulatory Affairs Merck Generics (Mylan).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

No holdings in Karolinska Development.